Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus regorafenib in unresectable or recurrent cholangiocarcinoma
ChiCTR2000040139Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and regorafenib in cholangiocarcinoma (CCA), sponsored by Tongji Hospital. Primary endpoints: 6-month progression-free survival rate and Progression-free survival (PFS). Planned start Dec 2020; status: not yet recruiting.
02
Drugs
tislelizumabregorafenib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2000040139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040139.